Boka, Gabor
Sanofi (France)
3 papers on CoChatORCID 0009-0000-4427-9507
Most cited papers
- Verified
Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 253
- Verified · note
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 218
- Verified
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-s)
Rosenstock, J., Hanefeld, M., Shamanna, P., Min, K. W., Boka, G., Miossec, P., Zhou, T., Muehlen-Bartmer, I., & Ratner, R. E. (2014) · Journal of Diabetes and its Complications
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 130
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free